PetVivo (US:PETV)2026-02-17 23:02Financial Data and Key Metrics Changes - Revenues for the nine months ended December 31, 2025, totaled $887,000, a decrease of 2% from the same year-ago period [17] - Gross profit for the first nine months was $551,500, or 62.2% of revenues, down from 89% of revenues in the same period a year ago [19] - Net loss for the first nine months was $7.5 million, or 27 cents per share, compared to a net loss of $6 million, or 30 cents a share for the same year-ago period [22] - Total operating expenses decreased 2% to $6.7 million compared to the same year-ago period [21] - Current assets totaled $1.4 million, while current liabilities significantly reduced to $980,000 from $4.2 million a year ago [23][24] Business Line Data and Key Metrics Changes - Sales of Spryng products totaled $400,800, while sales of PrecisePRP products totaled $486,000, indicating a shift in sales mix [17] - The decrease in revenues was primarily due to a decline in Spryng product sales, offset by an increase in PrecisePRP sales [18] - The company plans to re-implement special promotions to incentivize distributors and veterinary clinics to improve Spryng sales [18] Market Data and Key Metrics Changes - The Canadian animal healthcare market is projected to grow at a CAGR of 6.8% to exceed $4.4 billion by 2031 [25] - The European animal health market is estimated at over $16.6 billion today and is projected to grow at a CAGR of 8.6% to $34.8 billion by 2033 [15] Company Strategy and Development Direction - The company is focusing on creating rapid growth and market expansion opportunities, including strong recurring revenues [2] - Strategic alliances with partners like Digital Landia aim to enhance the veterinary industry through innovative AI solutions [3] - The launch of PetVivo AI, an AI-powered software platform for veterinarians, is expected to provide a strong first-mover advantage [4] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, expecting continued sales momentum and market penetration for fiscal 2026 and beyond [31] - The company is in advanced discussions with an outside sales and marketing firm to enhance its distribution network [31] - Management highlighted the importance of educating customers on the combined benefits of Spryng and PrecisePRP to drive future sales [19] Other Important Information - The company appointed Josh Ruben to its board of directors, bringing extensive experience in healthcare and life sciences [16] - The partnership with Veterinary Growth Partners aims to promote Spryng and PrecisePRP products to over 7,300 veterinary clinics [8] Q&A Session Summary Question: Updates on getting on the NASDAQ listings - The company is working towards uplisting on the New York AMEX, contingent on stock price and market conditions [34] Question: Can you talk about the previous guidance given on last conference call? - Management indicated that previous guidance was around $2 million-$2.5 million for fiscal year, but recent sales trends have affected expectations [37][38] Question: Are you pushing out the uptick in sales? - Management clarified that the sales model has changed, and they are focusing on spreading sales more evenly across quarters [40] Question: Can you talk about the CapEx required for the rollout of the Digital Landia platform? - The onboarding process for veterinarians is streamlined, and CapEx is minimal as Digital Landia will handle most of the implementation [42][51] Question: Will PetVivo recognize revenues from the implementation of the veterinarian system? - Yes, the company expects to recognize revenues as veterinarians implement the system and benefit from cost savings [46] Question: Do you have expectations for revenues and PNL? - Management refrained from providing specific revenue guidance at this time [52][53]